Parents of children and adolescents who have bipolar disorder have a new treatment tool. The American Academy of Child and Adolescent Psychiatry (AACAP) has released the new Parents’ Medication Guide for Bipolar Disorder in Children & Adolescents.
A cooperative venture between the National Bipolar Foundation and the MedicAlert Foundation has produced “Safe 'til Stable,” an innovative emergency response service that provides a safety net for
Abnormalities in the genes that control circadian rhythms (rhythms of approximately 24 hours, also called biological clock) contribute to the development of bipolar disorder (manic depression), suggests a study presented at the Eighth International Conference on bipolar disorder. The conference was held in Pittsburgh between June 25-27 of 2009. The symposia, rapid communications, and poster abstracts for the 8th ICBD, published in the journal, "Bipolar Disorders", Volume 11, Supplement 1, 2009.
Finding may lead to development of new treatments for bipolar disorder.
WellPoint, Inc. (NYSE: WLP), the nation's largest health benefits company and its affiliated health plans, announced today the expansion of its innovative disease management program designed to help improve the care accessed by members in its affiliated health plans suffering from Bipolar Disorder, a disease that impacts over 5.7 million Americans each year. The Bipolar Condition Care Program will help facilitate treatment adherence and knowledge of their illness for members with Bipolar Disorder.
Bipolar disorder (BD) identified in childhood often persisted into adulthood in the first large follow-up study of its kind. Forty-four percent of children diagnosed with BD continued to have manic episodes as adults, in the study by NIMH grantee Barbara Geller, M.D., and colleagues at Washington University in St. Louis. They report on their findings in the October issue of the Archives of General Psychiatry.
AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended-Release Tablets for the acute treatment of the depressive episodes associated with bipolar disorder, the manic and mixed episodes associated with bipolar I disorder, and the maintenance treatment of bipolar I disorder as adjunctive therapy to lithium or divalproex. SEROQUEL XR is the first medication approved by the FDA for the once-daily acute treatment of both depressive and manic episodes associated with bipolar disorder.1
Bipolar disorder is one of the most important psychiatric diseases, often associated with considerable treatment needs and tremendous social and occupational burden for both the individual and family (Pini et al., 2005). Previously also labelled manic-depressive illness, bipolar disorder is typically referred to as an episodic, yet lifelong and clinically severe mood (or affective) disorder.
The largest genetic analysis of its kind to date for bipolar disorder has implicated machinery involved in the balance of sodium and calcium in brain cells. Researchers supported in part by the National Institute of Mental Health, part of the National Institutes of Health, found an association between the disorder and variation in two genes that make components of channels that manage the flow of the elements into and out of cells, including neurons.
For the 5.7 million Americans with bipolar disorder, finding effective treatments can pose a serious challenge. But recent research has shown promise for expanding the number of medicines that can be used to prevent the manic “highs” and depressed “lows” that characterize this condition.
Medications that target the protein BAG1, which regulates a process that can trigger symptoms in people who have bipolar disorder, may offer a new way of treating the disease, according to NIMH scientists.
People with bipolar disorder, also called manic depressive illness, experience unusually intense emotional states that occur in distinct periods called mood episodes. An overly joyful or overexcited state is called a manic episode, and an extremely sad or hopeless state is called a depressive episode.
In any report of an epidemic there should be a description of the disease of which the epidemic is comprised and mention of the test by which the disease is diagnosed. But nowhere is there mention of a physical abnormality-gross, microscopic or chemical, to make it a disease.
AstraZeneca announced FDA has approved SEROQUEL for the maintenance treatment of patients with bipolar I disorder, as adjunct therapy to lithium or divalproex.
Despite intriguing findings that omega-3 fatty acid supplements could alleviate depression symptoms, there is still not enough evidence to say whether omega-3s are useful treatments for people with bipolar disorder.
Youngsters with pediatric bipolar disorder and healthy peers who have first-degree relatives with bipolar disorder share the same difficulty labeling facial emotions.
Scientists may be able to develop faster-acting medications for the manic phase of bipolar disorder.
Patients with frequently relapsing bipolar disorder had a significant delay in the time to an initial relapse when risperidone long-acting injection.
Divalproex sodium (Depakote) has efficacy for significantly improving symptoms of bipolar I disorder in children and adolescents.